Biosimilars Market Research Reports
Biosimilars (otherwise termed follow-on-biologics, or FOBs for short) stand for the versions of biopharmaceuticals, which have the resembling but not identical parent molecule, and are created either by living organisms or from living micro-organisms by way of rDNA (recombinant DNA) or supervised gene expression technologies. The approval of Biosimilars occurs via strictly defined regulatory paths based on whether FOBs have shown comparability with their reference substance.
The worldwide Biosimilars Market is anticipated to surpass a EUR 14.9bn mark by end 2018. The major drivers encompass cost efficiency of biosimilars versus their high-priced analogues, the enlarging thirst for biotechnology drugs, imminent biotech drugs’ patent expiries, the planet’s aging population, and the rising frequency of critical illnesses. The illustrious actors on the global Biosimilars stage encompass Biocon, Intas Biopharmaceuticals, Cipla, Biopartners, Hospira, Wockhardt, Teva Pharmaceutical Industries, Sandoz International, amidst others.
The Catalogue’s research reports offer world, region and nation-wise analyses of the Biosimilars Market development over various time periods. The researches are lavish with discussions of the Biosimilars Industry growth rate, structure and capacity. The market trends, growth obstacles/stimulators, key products and those in R&D stage, and more issues are studied in the reports. Additionally, the research reports indicate and profile the leading players and hoped-for entrants, and offer market projections and forecasts.
... , Key Drivers, Markets and Trends in 2013 Summary GlobalData’s 'PharmaSphere: Global Biosimilars Strategy - Regulatory Landscape, Key Drivers, Markets and Trends ... and emerging markets Identify the key domestic players in various biosimilar markets, including South Korea, Japan and emerging markets such ...
May, 2013 152 pages... analysis of the trends which are shaping its development. Biosimilars in Emerging Markets is a 2-volume report which provides both a comprehensive overview of the ... over safety and quality. Volume 2 brings together highly-detailed market analysis with contributions from local industry experts whose clear ...
Mar, 2013 226 pagesThe growth in the biosimilar opportunity will be driven by several patent expiries of mega-blockbuster biologics in the next 5 years. Between 2012 and 2017, over $60b worth of sales of biologics in the US/EU will lose patent protection. Out of them, Roche’s/Biogen Idec’s Rituxan/MabThera (rituximab), Merck ...
Feb, 2013 45 pages... therapy brings significant burden on patients despite relatively low co-pay in Japan – and this will push individuals and DPC Hospitals to use ... macro forces as compared to generics, a number of companies aim to exploit this – Japan has seen a flood like consolidation and partnering activities in biosimilar ...
Jan, 2013 32 pages... next couple of years and are paving the way for biosimilar antibodies. The first Avastin biosimilars are already in clinical trials and ... diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on: Drug ...
Nov, 2012 64 pagesThe present Competitive Intelligence Report about TNF Antibodies –Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha or its receptor used to treat various inflammatory and autoimmune diseases as of November 2012. ...
Nov, 2012 82 pages... (2011 sales of over US$ 5.5 bln). Herceptin is approved and marketed for Her2 positive breast and gastric cancer. Genentech and Roche are ... cancer. In addition, the report lists company-specific R&D pipelines of Her2 antibodies. Competitor projects are listed in a tabular format providing information on: Drug ...
Nov, 2012 44 pagesThe present Competitive Intelligence Report about EGF-R Antibodies –Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of December 2012. Purchase of the downloadable pdf report ...
Dec, 2012 38 pages... Synagis Prolia/Xgeva Soliris Stelara Zenapax More than 140 biosimilar antibodies are in the pipeline with the first molecules approved ... with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information ...
Dec, 2012 142 pages... share, need to introduce new biosimilars over the next few years with a specific focus on the products in demand. Licensing deals are expected to expand the pipelines of established players, as well as new market entrants. The global biosimilar market, estimated at US$2 billion in ...
Nov, 2012 354 pages... business intelligence provider, has released its latest research “Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway ... research and in-house analysis by GBI Research’s team of industry experts. Cell culture technology is used to carry out processes external to the natural ...
Nov, 2012 75 pages... acceptability of biosimilars is higher in the domestic market. Biosimilar substitution is automatic and can take place as soon as a biosimilar is launched. “India Biosimilar Market Analysis” research report by KuicK research gives detailed insight on various aspects related the biosimilar market in India ...
Aug, 2012 80 pages... intelligence provider, has released its latest report, “Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the ... categories. It also provides the drivers and restraints affecting the biosimilars market, as well as the business environment and the key success ...
Jul, 2012 141 pages... business intelligence provider, has released its latest report, “Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing ... and threats. The report also provides information on the global biosimilars pipeline. Also discussed in detail are success factors for the ...
Jun, 2012 88 pages... The position, activity, products, pipeline and plans of 50 leading players in the field The Challenge for Industry The development of a biosimilar presents a series of challenges to traditional generic drug manufacturers seeking to enter the sector. To succeed, a company must have good financial backing ...
Jan, 2012 200 pages... other aspects of the field, including these: Developments in technology to aid biosimilar production Incidence and prevalence of diseases affecting demand for the ... those substitutes, helping you stay ahead. Nine ways Biosimilars and Follow-On Biologics: World Market 2013-2023 helps you In particular, then ...
Apr, 2013 235 pages... business intelligence provider, has released its latest research, “Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and ... your R&D pipeline through the identification and understanding of the key strategy for your drug. Identify the key players best positioned ...
Dec, 2012 78 pages... GBI Research, the leading business intelligence provider, has released its latest report, “Biosimilars Approval Pathways in the US and Europe – Development and ... industry. Scope The report covers: Data and analysis on the biosimilar market in the leading geographies of the world – the US, the UK, Germany ...
Apr, 2011 130 pagesThis report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for US, Europe, and Japan. ... , Shantha Biotechnics Ltd., Teva Pharmaceutical Industries Ltd., and Wockhardt Ltd. Market data and analytics are derived from primary and secondary ...
Apr, 2012 348 pagesThe new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated ...
May, 2013 301 pages... This report forecasts that for EPO, G-CSF and HGH, total biosimilar product sales by 2015 are estimated at US$342 million, of which US$159 ... appear which will significantly increase these estimates. Global Biosimilars: Identifying 2nd generation opportunities is a new, critical 190+ page management report, ...
Jan, 2011 194 pagesThis report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for US, Europe, and Japan. ... , Shantha Biotechnics Ltd., Teva Pharmaceutical Industries Ltd., and Wockhardt Ltd. Market data and analytics are derived from primary and secondary ...
Apr, 2010 390 pages... in the global biosimilars market. The global biosimilars market is expected to be worth US$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. The main ...
Sep, 2009 189 pages
